APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Viral Vector and Plasmid DNA

Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.

Selected research

Industry Growth & Trends

Global Viral Vector and Plasmid DNA Industry Growth and Trends Forecast to 2032

Report ID 173895720127 December 2025121 pages

Choose your research edition.

Industry ResearchViral Vector and Plasmid DNA Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Viral Vector and Plasmid DNA Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Viral Vector and Plasmid DNA Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viral Vector and Plasmid DNA Market Outlook and Growth Opportunities 2026210 pages · $4,250 USDMarket Analysis & ForecastGlobal Viral Vector and Plasmid DNA Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.

According to APO Research, the global Viral Vector and Plasmid DNA market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

Report Scope

Read the full market overview

This report provides a structured, data-driven view of the global Viral Vector and Plasmid DNA market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Viral Vector and Plasmid DNA market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Viral Vector and Plasmid DNA market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Viral Vector and Plasmid DNA.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Viral Vector and Plasmid DNA market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Viral Vector and Plasmid DNA Market by Company

Brammer Bio

Oxford BioMedica

Cobra Biologics

FinVector

Lonza

BioReliance

MolMed

FUJIFILM Diosynth Biotechnologies

UniQure

Aldevron

Richter-Helm

Eurogentec

OBiO Technology

Yposkesi

Cell and Gene Therapy Catapult

MassBiologics

Biovian

VGXI

Gene Synthesis

PlasmidFactory

Jikai Gene

Viral Vector and Plasmid DNA Segment by Type

Plasmid DNA

Viral Vector

Viral Vector and Plasmid DNA Segment by Application

Cancer

Virus Infection

Hereditary Disease

Viral Vector and Plasmid DNA Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vector and Plasmid DNA market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Vector and Plasmid DNA and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vector and Plasmid DNA.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Viral Vector and Plasmid DNA companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Viral Vector and Plasmid DNA Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Viral Vector and Plasmid DNA Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Viral Vector and Plasmid DNA Market Share by Region (2021-2026) Table 4. Global Viral Vector and Plasmid DNA Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Viral Vector and Plasmid DNA Market Share by Region (2027-2032) Table 6. Global Viral Vector and Plasmid DNA Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Viral Vector and Plasmid DNA Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Viral Vector and Plasmid DNA Market Size Share by Type (2021-2026) Table 9. Global Viral Vector and Plasmid DNA Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Viral Vector and Plasmid DNA Market Size Share Forecasted by Type (2027-2032) Table 11. North America Viral Vector and Plasmid DNA Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Viral Vector and Plasmid DNA Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Viral Vector and Plasmid DNA Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Viral Vector and Plasmid DNA Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Viral Vector and Plasmid DNA Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Viral Vector and Plasmid DNA Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Viral Vector and Plasmid DNA Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Viral Vector and Plasmid DNA Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Viral Vector and Plasmid DNA Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Viral Vector and Plasmid DNA Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Viral Vector and Plasmid DNA Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Viral Vector and Plasmid DNA Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Viral Vector and Plasmid DNA Market Size Share by Application (2021-2026) Table 24. Global Viral Vector and Plasmid DNA Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Viral Vector and Plasmid DNA Market Size Share Forecasted by Application (2027-2032) Table 26. North America Viral Vector and Plasmid DNA Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Viral Vector and Plasmid DNA Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Viral Vector and Plasmid DNA Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Viral Vector and Plasmid DNA Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Viral Vector and Plasmid DNA Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Viral Vector and Plasmid DNA Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Viral Vector and Plasmid DNA Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Viral Vector and Plasmid DNA Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Viral Vector and Plasmid DNA Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Viral Vector and Plasmid DNA Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Viral Vector and Plasmid DNA Industry Trends Table 37. Viral Vector and Plasmid DNA Industry Drivers Table 38. Viral Vector and Plasmid DNA Industry Opportunities and Challenges Table 39. Viral Vector and Plasmid DNA Industry Restraints Table 40. Global Viral Vector and Plasmid DNA Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Viral Vector and Plasmid DNA Revenue Market Share by Company (2021-2026) Table 42. Global Viral Vector and Plasmid DNA Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Viral Vector and Plasmid DNA Key Company Headquarters & Area Served Table 44. Global Viral Vector and Plasmid DNA Company, Product Type & Application Table 45. Global Viral Vector and Plasmid DNA Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Viral Vector and Plasmid DNA by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Brammer Bio Company Information Table 49. Brammer Bio Business Overview Table 50. Brammer Bio Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Brammer Bio Viral Vector and Plasmid DNA Product Portfolio Table 52. Brammer Bio Recent Development Table 53. Oxford BioMedica Company Information Table 54. Oxford BioMedica Business Overview Table 55. Oxford BioMedica Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Oxford BioMedica Viral Vector and Plasmid DNA Product Portfolio Table 57. Oxford BioMedica Recent Development Table 58. Cobra Biologics Company Information Table 59. Cobra Biologics Business Overview Table 60. Cobra Biologics Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Cobra Biologics Viral Vector and Plasmid DNA Product Portfolio Table 62. Cobra Biologics Recent Development Table 63. FinVector Company Information Table 64. FinVector Business Overview Table 65. FinVector Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. FinVector Viral Vector and Plasmid DNA Product Portfolio Table 67. FinVector Recent Development Table 68. Lonza Company Information Table 69. Lonza Business Overview Table 70. Lonza Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Lonza Viral Vector and Plasmid DNA Product Portfolio Table 72. Lonza Recent Development Table 73. BioReliance Company Information Table 74. BioReliance Business Overview Table 75. BioReliance Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. BioReliance Viral Vector and Plasmid DNA Product Portfolio Table 77. BioReliance Recent Development Table 78. MolMed Company Information Table 79. MolMed Business Overview Table 80. MolMed Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. MolMed Viral Vector and Plasmid DNA Product Portfolio Table 82. MolMed Recent Development Table 83. FUJIFILM Diosynth Biotechnologies Company Information Table 84. FUJIFILM Diosynth Biotechnologies Business Overview Table 85. FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Product Portfolio Table 87. FUJIFILM Diosynth Biotechnologies Recent Development Table 88. UniQure Company Information Table 89. UniQure Business Overview Table 90. UniQure Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. UniQure Viral Vector and Plasmid DNA Product Portfolio Table 92. UniQure Recent Development Table 93. Aldevron Company Information Table 94. Aldevron Business Overview Table 95. Aldevron Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Aldevron Viral Vector and Plasmid DNA Product Portfolio Table 97. Aldevron Recent Development Table 98. Richter-Helm Company Information Table 99. Richter-Helm Business Overview Table 100. Richter-Helm Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Richter-Helm Viral Vector and Plasmid DNA Product Portfolio Table 102. Richter-Helm Recent Development Table 103. Eurogentec Company Information Table 104. Eurogentec Business Overview Table 105. Eurogentec Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Eurogentec Viral Vector and Plasmid DNA Product Portfolio Table 107. Eurogentec Recent Development Table 108. OBiO Technology Company Information Table 109. OBiO Technology Business Overview Table 110. OBiO Technology Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. OBiO Technology Viral Vector and Plasmid DNA Product Portfolio Table 112. OBiO Technology Recent Development Table 113. Yposkesi Company Information Table 114. Yposkesi Business Overview Table 115. Yposkesi Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Yposkesi Viral Vector and Plasmid DNA Product Portfolio Table 117. Yposkesi Recent Development Table 118. Cell and Gene Therapy Catapult Company Information Table 119. Cell and Gene Therapy Catapult Business Overview Table 120. Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Product Portfolio Table 122. Cell and Gene Therapy Catapult Recent Development Table 123. MassBiologics Company Information Table 124. MassBiologics Business Overview Table 125. MassBiologics Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. MassBiologics Viral Vector and Plasmid DNA Product Portfolio Table 127. MassBiologics Recent Development Table 128. Biovian Company Information Table 129. Biovian Business Overview Table 130. Biovian Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Biovian Viral Vector and Plasmid DNA Product Portfolio Table 132. Biovian Recent Development Table 133. VGXI Company Information Table 134. VGXI Business Overview Table 135. VGXI Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. VGXI Viral Vector and Plasmid DNA Product Portfolio Table 137. VGXI Recent Development Table 138. Gene Synthesis Company Information Table 139. Gene Synthesis Business Overview Table 140. Gene Synthesis Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Gene Synthesis Viral Vector and Plasmid DNA Product Portfolio Table 142. Gene Synthesis Recent Development Table 143. PlasmidFactory Company Information Table 144. PlasmidFactory Business Overview Table 145. PlasmidFactory Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. PlasmidFactory Viral Vector and Plasmid DNA Product Portfolio Table 147. PlasmidFactory Recent Development Table 148. Jikai Gene Company Information Table 149. Jikai Gene Business Overview Table 150. Jikai Gene Viral Vector and Plasmid DNA Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 151. Jikai Gene Viral Vector and Plasmid DNA Product Portfolio Table 152. Jikai Gene Recent Development Table 153. North America Viral Vector and Plasmid DNA Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. North America Viral Vector and Plasmid DNA Market Size by Country (2021-2026) & (US$ Million) Table 155. North America Viral Vector and Plasmid DNA Market Share by Country (2021-2026) Table 156. North America Viral Vector and Plasmid DNA Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. North America Viral Vector and Plasmid DNA Market Share Forecast by Country (2027-2032) Table 158. Europe Viral Vector and Plasmid DNA Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Europe Viral Vector and Plasmid DNA Market Size by Country (2021-2026) & (US$ Million) Table 160. Europe Viral Vector and Plasmid DNA Market Share by Country (2021-2026) Table 161. Europe Viral Vector and Plasmid DNA Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Europe Viral Vector and Plasmid DNA Market Share Forecast by Country (2027-2032) Table 163. Asia-Pacific Viral Vector and Plasmid DNA Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Asia-Pacific Viral Vector and Plasmid DNA Market Size by Country (2021-2026) & (US$ Million) Table 165. Asia-Pacific Viral Vector and Plasmid DNA Market Share by Country (2021-2026) Table 166. Asia-Pacific Viral Vector and Plasmid DNA Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Asia-Pacific Viral Vector and Plasmid DNA Market Share Forecast by Country (2027-2032) Table 168. Latin America Viral Vector and Plasmid DNA Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Latin America Viral Vector and Plasmid DNA Market Size by Country (2021-2026) & (US$ Million) Table 170. Latin America Viral Vector and Plasmid DNA Market Share by Country (2021-2026) Table 171. Latin America Viral Vector and Plasmid DNA Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Latin America Viral Vector and Plasmid DNA Market Share Forecast by Country (2027-2032) Table 173. Middle East & Africa Viral Vector and Plasmid DNA Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country (2021-2026) & (US$ Million) Table 175. Middle East & Africa Viral Vector and Plasmid DNA Market Share by Country (2021-2026) Table 176. Middle East & Africa Viral Vector and Plasmid DNA Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Middle East & Africa Viral Vector and Plasmid DNA Market Share Forecast by Country (2027-2032) Table 178. Research Programs/Design for This Report Table 179. Authors List of This Report Table 180. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Viral Vector and Plasmid DNA Product Image Figure 3. Global Viral Vector and Plasmid DNA Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Viral Vector and Plasmid DNA Market Size (2021-2032) & (US$ Million) Figure 5. Global Viral Vector and Plasmid DNA Market Share by Region: 2025 VS 2032 Figure 6. Global Viral Vector and Plasmid DNA Market Share by Region (2021-2032) Figure 7. North America Viral Vector and Plasmid DNA Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Viral Vector and Plasmid DNA Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Viral Vector and Plasmid DNA Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Viral Vector and Plasmid DNA Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Viral Vector and Plasmid DNA Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Plasmid DNA Image Figure 13. Global Plasmid DNA Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Viral Vector Image Figure 15. Global Viral Vector Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Viral Vector and Plasmid DNA Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Viral Vector and Plasmid DNA Market Share by Type 2025 VS 2032 Figure 18. North America Viral Vector and Plasmid DNA Market Size Share by Type (2021-2032) Figure 19. Europe Viral Vector and Plasmid DNA Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Viral Vector and Plasmid DNA Market Size Share by Type (2021-2032) Figure 21. Latin America Viral Vector and Plasmid DNA Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Viral Vector and Plasmid DNA Market Size Share by Type (2021-2032) Figure 23. Cancer Image Figure 24. Global Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Virus Infection Image Figure 26. Global Virus Infection Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Hereditary Disease Image Figure 28. Global Hereditary Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Global Viral Vector and Plasmid DNA Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Viral Vector and Plasmid DNA Market Share by Application 2025 VS 2032 Figure 31. North America Viral Vector and Plasmid DNA Market Size Share by Application (2021-2032) Figure 32. Europe Viral Vector and Plasmid DNA Market Size Share by Application (2021-2032) Figure 33. Asia-Pacific Viral Vector and Plasmid DNA Market Size Share by Application (2021-2032) Figure 34. Latin America Viral Vector and Plasmid DNA Market Size Share by Application (2021-2032) Figure 35. Middle East and Africa Viral Vector and Plasmid DNA Market Size Share by Application (2021-2032) Figure 36. Global Top 5 and 10 Viral Vector and Plasmid DNA Players Market Share by Revenue in 2025 Figure 37. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 38. North America Viral Vector and Plasmid DNA Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 39. North America Viral Vector and Plasmid DNA Market Share by Country: 2021 VS 2025 VS 2032 Figure 40. North America Viral Vector and Plasmid DNA Market Share by Country (2021-2032) Figure 41. Europe Viral Vector and Plasmid DNA Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. Europe Viral Vector and Plasmid DNA Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Viral Vector and Plasmid DNA Market Share by Country (2021-2032) Figure 44. Asia-Pacific Viral Vector and Plasmid DNA Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. Asia-Pacific Viral Vector and Plasmid DNA Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. Asia-Pacific Viral Vector and Plasmid DNA Market Share by Country (2021-2032) Figure 47. Latin America Viral Vector and Plasmid DNA Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Latin America Viral Vector and Plasmid DNA Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Latin America Viral Vector and Plasmid DNA Market Share by Country (2021-2032) Figure 50. Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Middle East & Africa Viral Vector and Plasmid DNA Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Middle East & Africa Viral Vector and Plasmid DNA Market Share by Country (2021-2032) Figure 53. Years Considered Figure 54. Research Process Figure 55. Key Executives Interviewed

Scope & coverage.

Types
  • Plasmid DNA
  • Viral Vector
Applications
  • Cancer
  • Virus Infection
  • Hereditary Disease
Companies covered
  • Brammer Bio
  • Oxford BioMedica
  • Cobra Biologics
  • FinVector
  • Lonza
  • BioReliance
  • MolMed
  • FUJIFILM Diosynth Biotechnologies
  • UniQure
  • Aldevron
  • Richter-Helm
  • Eurogentec
  • OBiO Technology
  • Yposkesi
  • Cell and Gene Therapy Catapult
  • MassBiologics
  • Biovian
  • VGXI
  • Gene Synthesis
  • PlasmidFactory
  • Jikai Gene

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Viral Vector and Plasmid DNA Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Viral Vector and Plasmid DNA Market Size by Region (2021-2032)
  5. 1.4.1 Global Viral Vector and Plasmid DNA Market Size by Region (2021-2026)
  6. 1.4.2 Global Viral Vector and Plasmid DNA Market Size by Region (2027-2032)
  7. 1.5 Key Regions Viral Vector and Plasmid DNA Market Size (2021-2032)
  8. 1.5.1 North America Viral Vector and Plasmid DNA Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Viral Vector and Plasmid DNA Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Viral Vector and Plasmid DNA Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Viral Vector and Plasmid DNA Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Viral Vector and Plasmid DNA Market Size Growth Rate (2021-2032)
2 Viral Vector and Plasmid DNA Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Plasmid DNA
  3. 2.1.2 Viral Vector
  4. 2.2 Global Viral Vector and Plasmid DNA Market Size by Type
  5. 2.2.1 Global Viral Vector and Plasmid DNA Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Viral Vector and Plasmid DNA Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Viral Vector and Plasmid DNA Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Viral Vector and Plasmid DNA Market Size by Regions
  9. 2.3.1 North America Viral Vector and Plasmid DNA Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Viral Vector and Plasmid DNA Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Viral Vector and Plasmid DNA Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Viral Vector and Plasmid DNA Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Viral Vector and Plasmid DNA Market Size Breakdown by Type (2021-2026)
3 Viral Vector and Plasmid DNA Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Cancer
  3. 3.1.2 Virus Infection
  4. 3.1.3 Hereditary Disease
  5. 3.2 Global Viral Vector and Plasmid DNA Market Size by Application
  6. 3.2.1 Global Viral Vector and Plasmid DNA Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Viral Vector and Plasmid DNA Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Viral Vector and Plasmid DNA Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Viral Vector and Plasmid DNA Market Size by Regions
  10. 3.3.1 North America Viral Vector and Plasmid DNA Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Viral Vector and Plasmid DNA Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Viral Vector and Plasmid DNA Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Viral Vector and Plasmid DNA Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Viral Vector and Plasmid DNA Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Viral Vector and Plasmid DNA Industry Trends
  2. 4.2 Viral Vector and Plasmid DNA Industry Drivers
  3. 4.3 Viral Vector and Plasmid DNA Industry Opportunities and Challenges
  4. 4.4 Viral Vector and Plasmid DNA Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Viral Vector and Plasmid DNA Revenue (2021-2026)
  2. 5.2 Global Viral Vector and Plasmid DNA Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Viral Vector and Plasmid DNA Key Company Headquarters & Area Served
  4. 5.4 Global Viral Vector and Plasmid DNA Company, Product Type & Application
  5. 5.5 Global Viral Vector and Plasmid DNA Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Viral Vector and Plasmid DNA Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Viral Vector and Plasmid DNA Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Viral Vector and Plasmid DNA Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Brammer Bio
  2. 6.1.1 Brammer Bio Company Information
  3. 6.1.2 Brammer Bio Business Overview
  4. 6.1.3 Brammer Bio Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Brammer Bio Viral Vector and Plasmid DNA Product Portfolio
  6. 6.1.5 Brammer Bio Recent Developments
  7. 6.2 Oxford BioMedica
  8. 6.2.1 Oxford BioMedica Company Information
  9. 6.2.2 Oxford BioMedica Business Overview
  10. 6.2.3 Oxford BioMedica Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Oxford BioMedica Viral Vector and Plasmid DNA Product Portfolio
  12. 6.2.5 Oxford BioMedica Recent Developments
  13. 6.3 Cobra Biologics
  14. 6.3.1 Cobra Biologics Company Information
  15. 6.3.2 Cobra Biologics Business Overview
  16. 6.3.3 Cobra Biologics Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Cobra Biologics Viral Vector and Plasmid DNA Product Portfolio
  18. 6.3.5 Cobra Biologics Recent Developments
  19. 6.4 FinVector
  20. 6.4.1 FinVector Company Information
  21. 6.4.2 FinVector Business Overview
  22. 6.4.3 FinVector Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 FinVector Viral Vector and Plasmid DNA Product Portfolio
  24. 6.4.5 FinVector Recent Developments
  25. 6.5 Lonza
  26. 6.5.1 Lonza Company Information
  27. 6.5.2 Lonza Business Overview
  28. 6.5.3 Lonza Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Lonza Viral Vector and Plasmid DNA Product Portfolio
  30. 6.5.5 Lonza Recent Developments
  31. 6.6 BioReliance
  32. 6.6.1 BioReliance Company Information
  33. 6.6.2 BioReliance Business Overview
  34. 6.6.3 BioReliance Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 BioReliance Viral Vector and Plasmid DNA Product Portfolio
  36. 6.6.5 BioReliance Recent Developments
  37. 6.7 MolMed
  38. 6.7.1 MolMed Company Information
  39. 6.7.2 MolMed Business Overview
  40. 6.7.3 MolMed Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 MolMed Viral Vector and Plasmid DNA Product Portfolio
  42. 6.7.5 MolMed Recent Developments
  43. 6.8 FUJIFILM Diosynth Biotechnologies
  44. 6.8.1 FUJIFILM Diosynth Biotechnologies Company Information
  45. 6.8.2 FUJIFILM Diosynth Biotechnologies Business Overview
  46. 6.8.3 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Product Portfolio
  48. 6.8.5 FUJIFILM Diosynth Biotechnologies Recent Developments
  49. 6.9 UniQure
  50. 6.9.1 UniQure Company Information
  51. 6.9.2 UniQure Business Overview
  52. 6.9.3 UniQure Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 UniQure Viral Vector and Plasmid DNA Product Portfolio
  54. 6.9.5 UniQure Recent Developments
  55. 6.10 Aldevron
  56. 6.10.1 Aldevron Company Information
  57. 6.10.2 Aldevron Business Overview
  58. 6.10.3 Aldevron Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Aldevron Viral Vector and Plasmid DNA Product Portfolio
  60. 6.10.5 Aldevron Recent Developments
  61. 6.11 Richter-Helm
  62. 6.11.1 Richter-Helm Company Information
  63. 6.11.2 Richter-Helm Business Overview
  64. 6.11.3 Richter-Helm Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Richter-Helm Viral Vector and Plasmid DNA Product Portfolio
  66. 6.11.5 Richter-Helm Recent Developments
  67. 6.12 Eurogentec
  68. 6.12.1 Eurogentec Company Information
  69. 6.12.2 Eurogentec Business Overview
  70. 6.12.3 Eurogentec Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Eurogentec Viral Vector and Plasmid DNA Product Portfolio
  72. 6.12.5 Eurogentec Recent Developments
  73. 6.13 OBiO Technology
  74. 6.13.1 OBiO Technology Company Information
  75. 6.13.2 OBiO Technology Business Overview
  76. 6.13.3 OBiO Technology Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 OBiO Technology Viral Vector and Plasmid DNA Product Portfolio
  78. 6.13.5 OBiO Technology Recent Developments
  79. 6.14 Yposkesi
  80. 6.14.1 Yposkesi Company Information
  81. 6.14.2 Yposkesi Business Overview
  82. 6.14.3 Yposkesi Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Yposkesi Viral Vector and Plasmid DNA Product Portfolio
  84. 6.14.5 Yposkesi Recent Developments
  85. 6.15 Cell and Gene Therapy Catapult
  86. 6.15.1 Cell and Gene Therapy Catapult Company Information
  87. 6.15.2 Cell and Gene Therapy Catapult Business Overview
  88. 6.15.3 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Product Portfolio
  90. 6.15.5 Cell and Gene Therapy Catapult Recent Developments
  91. 6.16 MassBiologics
  92. 6.16.1 MassBiologics Company Information
  93. 6.16.2 MassBiologics Business Overview
  94. 6.16.3 MassBiologics Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 MassBiologics Viral Vector and Plasmid DNA Product Portfolio
  96. 6.16.5 MassBiologics Recent Developments
  97. 6.17 Biovian
  98. 6.17.1 Biovian Company Information
  99. 6.17.2 Biovian Business Overview
  100. 6.17.3 Biovian Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Biovian Viral Vector and Plasmid DNA Product Portfolio
  102. 6.17.5 Biovian Recent Developments
  103. 6.18 VGXI
  104. 6.18.1 VGXI Company Information
  105. 6.18.2 VGXI Business Overview
  106. 6.18.3 VGXI Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 VGXI Viral Vector and Plasmid DNA Product Portfolio
  108. 6.18.5 VGXI Recent Developments
  109. 6.19 Gene Synthesis
  110. 6.19.1 Gene Synthesis Company Information
  111. 6.19.2 Gene Synthesis Business Overview
  112. 6.19.3 Gene Synthesis Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Gene Synthesis Viral Vector and Plasmid DNA Product Portfolio
  114. 6.19.5 Gene Synthesis Recent Developments
  115. 6.20 PlasmidFactory
  116. 6.20.1 PlasmidFactory Company Information
  117. 6.20.2 PlasmidFactory Business Overview
  118. 6.20.3 PlasmidFactory Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 PlasmidFactory Viral Vector and Plasmid DNA Product Portfolio
  120. 6.20.5 PlasmidFactory Recent Developments
  121. 6.21 Jikai Gene
  122. 6.21.1 Jikai Gene Company Information
  123. 6.21.2 Jikai Gene Business Overview
  124. 6.21.3 Jikai Gene Viral Vector and Plasmid DNA Revenue, Global Share and Gross Margin (2021-2026)
  125. 6.21.4 Jikai Gene Viral Vector and Plasmid DNA Product Portfolio
  126. 6.21.5 Jikai Gene Recent Developments
7 North America
  1. 7.1 North America Viral Vector and Plasmid DNA Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Viral Vector and Plasmid DNA Market Size by Country (2021-2026)
  3. 7.3 North America Viral Vector and Plasmid DNA Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Viral Vector and Plasmid DNA Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Viral Vector and Plasmid DNA Market Size by Country (2021-2026)
  3. 8.3 Europe Viral Vector and Plasmid DNA Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Viral Vector and Plasmid DNA Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Viral Vector and Plasmid DNA Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Viral Vector and Plasmid DNA Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Viral Vector and Plasmid DNA Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Viral Vector and Plasmid DNA Market Size by Country (2021-2026)
  3. 10.3 South America Viral Vector and Plasmid DNA Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Viral Vector and Plasmid DNA Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Viral Vector and Plasmid DNA Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst